相关实验视频

Updated: Jan 10, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

拉胺A/C与卵巢癌的存活率之间的反相关性:对预测对基于税的化疗反应的影响

Elizabeth R Smith¹, Isaac R L Xu², Kathy Qi Cai³

¹Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, United States.

Gynecologic oncology reports

|November 28, 2025

概括

卵巢癌中的高拉敏A/C表达预示着生存率低下和帕克利塔克塞尔耐药性. 这一发现可能会导致新的生物标志物用于预测患者的结果和治疗敏感性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

帕克利塔塞尔是卵巢癌的关键化疗,但耐药性限制了其有效性,特别是在复发的情况下.
目前缺乏对帕克利塔克塞尔反应的预测生物标志物.
核胺A/C蛋白质影响细胞机制,并可能影响对帕克利塔塞尔诱导的细胞死亡的敏感性.

研究的目的:

调查卵巢癌组织中的拉敏A/C表达与患者存活率之间的关系.
确定拉敏A/C表达是否可以作为晚期卵巢癌中帕克利塔塞尔敏感性的预测生物标志物.

主要方法:

卵巢癌组织样本使用免疫染分析了拉胺A/C表达.
瘤被分为分层,分为拉胺A/C低和拉胺A/C高的两组.
总生存率 (OS) 和无进展生存率 (PFS) 使用卡普兰-梅尔分析进行了评估.

主要成果:

老年 (>60岁) 和高拉敏A/C表达与较低的整体存活率相关.
拉敏A/C表达是OS的独立预测因素.
与高表达组 (34.5个月) 相比,Lamin A / C低组 (58个月) 的中位数OS显著更长.

结论:

在初级卵巢瘤中强烈,广泛的拉敏A/C表达可能表明帕克利塔塞尔敏感性差和生存率降低.
拉敏A/C表达显示出作为卵巢癌中帕克利塔塞尔治疗结果的预测生物标志物的潜力.
这支持一种机制,即Lamin A/C通过微核化影响帕克利塔塞尔诱导的癌细胞死亡.

关键词:

化疗化疗是一种化学疗法.药物耐药性药物耐药性药物耐药性拉明A/C A/C 是一个类型.微核是微核中的一个.这些微管是微管子.线粒分裂 (mitosis) 是一种发生在细胞的过程.核包裹是一个核包裹.帕克利塔克塞尔是什么?

更多相关视频

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...